NVCR News and Press, NovoCure Limited From 06/06/23

Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpo...

Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoin...

Novocure (NASDAQ: NVCR) today announced that it will donate $3 million to Conquer Cancer ® , the ASCO Foundation, to advance cancer research and education. Conquer Cancer is a global community of advocates, patients, doctors, researchers, caregivers, and others dedicated to improving...

2023-05-27 06:14:00 ET You don't need much money to get started investing. And stocks with relatively low share prices have tremendous growth prospects. Three Fool.com contributors identified no-brainer healthcare stocks to buy for under $100. Here's why they chose CRISPR Therapeu...

2023-05-16 10:48:58 ET NovoCure ( NASDAQ: NVCR ) shares rose on Tuesday to approach a three-month high after Wells Fargo upgraded the stock to Overweight from Equal Weight citing a positive Phase 3 readout for the company’s Tumor Treating Fields (TTFields) therapy next month....

2023-05-04 13:00:29 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q1 2023 Earnings Call May 04, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q1 2023 Earnings Call Transcript

2023-05-04 10:15:22 ET NovoCure Limited (NVCR) Q1 2023 Earnings Conference Call May 04, 2023 08:00 AM ET Company Participants Ingrid Goldberg - Vice President of Investor Relations William Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ash...

2023-05-04 07:16:09 ET NovoCure press release ( NASDAQ: NVCR ): Q1 GAAP EPS of -$0.50 misses by $0.16 . Revenue of $122.18M (-11.2% Y/Y) misses by $5.75M . The United States, Germany and Japan contributed $85.2 million, $15.1 million and $8....

Data from phase 3 LUNAR clinical trial in non-small cell lung cancer to be presented June 6 th at ASCO Annual Meeting Enrollment of phase 3 METIS clinical trial completed, the fourth phase 3 clinical trial to complete enrollment in last 18 months Novocure (NASDAQ: NVCR) toda...

2023-05-03 13:56:00 ET NovoCure ( NASDAQ: NVCR ) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open. The consensus EPS Estimate is -$0.34 (-750.0% Y/Y) and the consensus Revenue Estimate is $127.93M (-7.0% Y/Y). Over the last 1 year, ...